CN108770360B - 对癌性疾病进行分期、分型和治疗的手段和方法 - Google Patents

对癌性疾病进行分期、分型和治疗的手段和方法 Download PDF

Info

Publication number
CN108770360B
CN108770360B CN201780008861.6A CN201780008861A CN108770360B CN 108770360 B CN108770360 B CN 108770360B CN 201780008861 A CN201780008861 A CN 201780008861A CN 108770360 B CN108770360 B CN 108770360B
Authority
CN
China
Prior art keywords
cells
dcc
cancer
somatic
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780008861.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108770360A (zh
Inventor
克里斯托夫·克莱因
塞巴斯蒂安·谢特勒
梅勒妮·维尔纳·克莱因
马丁·霍夫曼
伊莎贝尔·霍达克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Regensburg
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Universitaet Regensburg
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Regensburg, Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Universitaet Regensburg
Publication of CN108770360A publication Critical patent/CN108770360A/zh
Application granted granted Critical
Publication of CN108770360B publication Critical patent/CN108770360B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201780008861.6A 2016-01-27 2017-01-27 对癌性疾病进行分期、分型和治疗的手段和方法 Active CN108770360B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
EP16152883.1 2016-01-27
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (2)

Publication Number Publication Date
CN108770360A CN108770360A (zh) 2018-11-06
CN108770360B true CN108770360B (zh) 2022-06-14

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780008861.6A Active CN108770360B (zh) 2016-01-27 2017-01-27 对癌性疾病进行分期、分型和治疗的手段和方法

Country Status (10)

Country Link
US (1) US11702701B2 (enExample)
EP (2) EP3199641B1 (enExample)
JP (1) JP2019508032A (enExample)
KR (1) KR20180102674A (enExample)
CN (1) CN108770360B (enExample)
AU (1) AU2017211976B2 (enExample)
CA (1) CA3012404A1 (enExample)
ES (1) ES2905208T3 (enExample)
SG (1) SG11201805990XA (enExample)
WO (1) WO2017129753A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
EP2503009A1 (en) * 2011-03-25 2012-09-26 Massimo Zollo Biomarker for detecting circulating tumor cells and related detecting methods and kit
WO2013009632A9 (en) * 2011-07-08 2013-10-24 The University Of Utah Research Foundation Methods of detecting hereditary cancer predisposition
WO2015023553A3 (en) * 2013-08-13 2015-04-23 Bionumerik Pharmaceuticals, Inc. Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673541B1 (en) 1998-09-18 2004-01-06 Micromet Ag DNA amplification of a single cell
EP3211099A1 (en) * 2011-12-10 2017-08-30 Abbott Molecular Inc. Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma
US10273538B2 (en) 2014-02-05 2019-04-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Error-free sequencing of DNA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
EP2503009A1 (en) * 2011-03-25 2012-09-26 Massimo Zollo Biomarker for detecting circulating tumor cells and related detecting methods and kit
WO2013009632A9 (en) * 2011-07-08 2013-10-24 The University Of Utah Research Foundation Methods of detecting hereditary cancer predisposition
WO2015023553A3 (en) * 2013-08-13 2015-04-23 Bionumerik Pharmaceuticals, Inc. Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chemoprevention for brain metastases;Van A Trinh等;《Curr Oncol Rep》;20111018;第14卷(第1期);第63-69页 *
Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection;M Picard等;《British Journal of Dermatology》;20140707;第171卷(第1期);摘要，第109页"患者选择和数据收集"、"BRAF状态测试"，第111页"突变"，第114页左栏第2-3段，表1 *
M Picard等.Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.《British Journal of Dermatology》.2014,第171卷(第1期),第108-114页. *
Quantitative measurement of melanoma spread in sentinel lymph nodes and survival;Anja Ulmer等;《PLoS Med》;20140218;第11卷(第2期);摘要，表2，第8页右栏倒数第1段 *

Also Published As

Publication number Publication date
AU2017211976B2 (en) 2022-09-22
US11702701B2 (en) 2023-07-18
JP2019508032A (ja) 2019-03-28
AU2017211976A1 (en) 2018-08-02
CN108770360A (zh) 2018-11-06
EP3199641B1 (en) 2021-09-29
KR20180102674A (ko) 2018-09-17
WO2017129753A8 (en) 2017-10-19
EP3199641A1 (en) 2017-08-02
WO2017129753A1 (en) 2017-08-03
ES2905208T3 (es) 2022-04-07
SG11201805990XA (en) 2018-08-30
CA3012404A1 (en) 2017-08-03
US20190062845A1 (en) 2019-02-28
EP3408411A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
TW201632629A (zh) 用於癌症診斷與預後的方法
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
CA2941594A1 (en) Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CN109476698B (zh) 基于基因的炎性肠病诊断
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
KR20180049093A (ko) 신규한 바이오마커 및 암의 치료 방법
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CN111405901B (zh) 含有miRNA的癌症治疗用医药组合物
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
CN116867908A (zh) 端粒的物理表征
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
CN108624683B (zh) Usp48基因突变在acth型垂体腺瘤分子诊断中的应用
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
CN108770360B (zh) 对癌性疾病进行分期、分型和治疗的手段和方法
US20040138441A1 (en) Novel gene functionally related to dyslexia
KR102647919B1 (ko) App 돌연변이 세포 및 이의 이용
US20090258344A1 (en) Methods for identifying risk of breast cancer and treatments thereof
KR20050008644A (ko) 위암에서의 유전자 발현 프로파일
US20030219787A1 (en) Novel human gene functionally related to dyslexia
CN113718033A (zh) 生物标记物在制备用于预测结直肠癌患者预后的试剂中的应用
KR20130048240A (ko) Ｐｃｂｐ―１ 항원에 대한 모노클로날 항체, 및 그의 용도
CN116356008A (zh) 先天性心脏病相关setd2基因新发变异位点及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant